Increased Immune Infiltration and Improved Prognosis of Head and Neck Squamous Cell Carcinoma Associated with Reduced Ancient Ubiquitous Protein 1 Gene Expression

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2024 Jun 11

PMID 38862860

Authors

Yi Wang

Qian Wu

Xiao Wei

Gang Huang

Guangyong Feng

Hui Xu

Xiaoxia Gou

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the molecular mechanism underlying the prognostic role of ancient ubiquitous protein 1 (AUP1) in head and neck squamous cell carcinoma (HNSCC) and its relationship with the tumor immune microenvironment. Various web resources were used to analyze the differential expression of AUP1 and its role in the HNSCC pathogenesis. A nomogram aimed at predicting 1-, 3-, and 5-year survival rates was developed based on the patient's clinicopathological characteristics and AUP1 expression pattern. Several algorithms and analytical tools were used to explore the correlation between AUP1 expression and sensitivity to immune checkpoint gene therapy by evaluating infiltrating immune cells in patients with HNSCC. Higher AUP1 mRNA and protein expression levels were observed in most tumors and HNSCC than in the normal tissues. High AUP1 expression was an independent predictive risk factor for the overall survival of patients as it was closely associated with the patients' T, M, clinical, and pathological stages and lymphovascular invasion in HNSCC. In conclusion, AUP1 is involved in the occurrence and progression of HNSCC, may be used as an independent prognostic factor in patients with HNSCC, and could serve as a potential intervention target to improve immunotherapy sensitivity in HNSCC.

References

Caudell J, Gillison M, Maghami E, Spencer S, Pfister D, Adkins D . NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022; 20(3):224-234. DOI: 10.6004/jnccn.2022.0016. View

Gu Z, Yao Y, Yang G, Zhu G, Tian Z, Wang R . Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Sci Transl Med. 2022; 14(661):eabo5987. DOI: 10.1126/scitranslmed.abo5987. View

Chi H, Xie X, Yan Y, Peng G, Strohmer D, Lai G . Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. Front Immunol. 2022; 13:1018685. PMC: 9575041. DOI: 10.3389/fimmu.2022.1018685. View

Liu G, Li W, Wang D, Liang H, Lv X, Ye Y . Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase.... JAMA Oncol. 2022; 8(4):553-561. PMC: 8855317. DOI: 10.1001/jamaoncol.2021.7366. View

Peng Z, Wang Y, Fan R, Gao K, Xie S, Wang F . Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge. Cancers (Basel). 2022; 14(17). PMC: 9454547. DOI: 10.3390/cancers14174111. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Chung C, Li J, Steuer C, Bhateja P, Johnson M, Masannat J . Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022; 28(11):2329-2338. PMC: 9167762. DOI: 10.1158/1078-0432.CCR-21-3849. View

Harrington K, Burtness B, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022; 41(4):790-802. PMC: 9902012. DOI: 10.1200/JCO.21.02508. View

Uppaluri R, Campbell K, Egloff A, Zolkind P, Skidmore Z, Nussenbaum B . Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020; 26(19):5140-5152. PMC: 7547532. DOI: 10.1158/1078-0432.CCR-20-1695. View

10.

Ruffin A, Li H, Vujanovic L, Zandberg D, Ferris R, Bruno T . Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2022; 23(3):173-188. PMC: 9992112. DOI: 10.1038/s41568-022-00531-9. View

11.

Emran T, Shahriar A, Mahmud A, Rahman T, Abir M, Siddiquee M . Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022; 12:891652. PMC: 9262248. DOI: 10.3389/fonc.2022.891652. View

12.

Rauf A, Abu-Izneid T, Khalil A, Imran M, Shah Z, Emran T . Berberine as a Potential Anticancer Agent: A Comprehensive Review. Molecules. 2021; 26(23). PMC: 8658774. DOI: 10.3390/molecules26237368. View

13.

Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View

14.

Zou W, Green D . Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy. Cell Metab. 2023; 35(7):1101-1113. PMC: 10527949. DOI: 10.1016/j.cmet.2023.06.003. View

15.

Zhu L, Zhu X, Wu Y . Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications. Biomolecules. 2022; 12(4). PMC: 9028125. DOI: 10.3390/biom12040580. View

16.

Goswami S, Zhang Q, Celik C, Reich E, Yilmaz O . Dietary fat and lipid metabolism in the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188984. PMC: 10937091. DOI: 10.1016/j.bbcan.2023.188984. View

17.

Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z . Lipid metabolism and cancer. J Exp Med. 2021; 218(1). PMC: 7754673. DOI: 10.1084/jem.20201606. View

18.

Mardinoglu A, Boren J . AUP1 (Ancient Ubiquitous Protein 1): A Molecular Link Between Hepatic Lipid Mobilization and VLDL Secretion. Arterioscler Thromb Vasc Biol. 2017; 37(4):609-610. DOI: 10.1161/ATVBAHA.117.309152. View

19.

Chang P, Lin Y, Yen H, Hueng D, Huang S, Li Y . Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. Cancer Cell Int. 2023; 23(1):62. PMC: 10080956. DOI: 10.1186/s12935-023-02912-y. View

20.

Chen C, Zhao W, Lu X, Ma Y, Zhang P, Wang Z . AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma. Cancer Sci. 2022; 113(8):2600-2615. PMC: 9357643. DOI: 10.1111/cas.15445. View